Yöntemler: Bu çalışma enine-kesitli ve gözlemsel bir modele sahiptir. Çalışmaya koroner anjiyografisi yapılan ardışık 112 hasta alındı (ortalama yaş: 59±9 yıl). Periferik kanda dolaşan enflamasyon hücreleri ve EPH (lenfositer ve monositer alanda CD34 + KDR + olarak tanımlanan) hücrelerin ateroskleroz varlığı, ciddiyeti, yaygınlığı ve kollateral gelişimi ile olan ilişkileri araştırıldı. Kollateral akım öngördürücülerinin belirlenmesinde lojistik regresyon analizi kullanıldı.
Introduction
Atherosclerosis is a chronic inflammatory disease, which develops as a process occurring in vessel wall, which begins with response to endothelial injury. Endothelial dysfunction is characterized with dysfunction and loss of monolayer cells covering the inside of the vessels, which is endothelium. Endothelial dysfunction is the first stage in atherosclerosis. The regenerative capacity of endothelium provides protection against atherosclerosis. Failure of the endothelial repair initiates atherosclerotic inflammation and lesion formation, so-called plaque, especially in non-laminar flow stress points in vascular bed (1) .
For a long time in vascular system, it is believed that the damaged endothelial cells can only be repaired or replaced by the proliferation and migration of neighboring endothelial cells (2) . However, this concept has changed together with determination of endothelial progenitor cells (EPC) having both of stem cell and endothelial cell markers and being able to transform into the endothelial phenotype (3) (4) (5) (6) .
Coronary angiogenesis and collateral growth are chronic adaptations to myocardial ischemia to restore coronary blood flow and salvage myocardium in the ischemic region. Coronary collateral development has potential protective roles such as limited infract size, less aneurysm formation in the ventricle wall, improved ventricular function, fewer future cardiovascular events and improved survival in patients with occlusive coronary lesions (7, 8) .
Endothelial progenitor cells have reparative features in vasculature and are the new aspect of collateral growth. Matsuo et al. (9) investigated whether or not number and function of EPCs were associated with the development of collateral formation in patients with single-vessel coronary artery disease (CAD) of chronic total occlusion and found that EPC-mediated angiogenesis might be associated with coronary collateral formation in humans. Lambiasi et al. (10) suggested that inadequate coronary collateral development is associated with reduced numbers of circulating EPCs in patients with isolated left anterior descending coronary artery disease.
Though few studies have reported the association of EPC with collateral growth, the role of EPC in collateral growth in multivessel CAD with multiple risk factors and their simultaneous association with inflammatory cells, especially monocytes has not been yet established.
In this study, we aimed to evaluate the relation of EPC and inflammatory cells with the presence and extent of CAD and the grade of coronary collateral development in patients with clinical suspicion of CAD.
Methods
This study has a cross-sectional and observational design. One hundred and twelve eligible outpatients who underwent coronary angiography with a suspicion of CAD at the Gazi University Departments of Cardiology between May 2008 and December 2008 were consecutively enrolled in this study. The local Ethics Committee of Gazi University Medical School has approved this study. All the patients gave written informed consent. Clinical characteristics, which consisted of multiple descriptors from each patient's history and physical examination, were collected by physicians from cardiology laboratory for each patient at the time of cardiac catheterization and were stored in the database of coronary angiography laboratory at our institution.
Patients with symptomatic peripheral vascular disease (transient ischemic attack, stroke, intermittent claudication, peripheral revascularization, or amputation), non-ischemic dilated cardiomyopathy, with evidence of ongoing infection or inflammation, recent acute coronary syndrome either with or without ST-segment elevation (at most one month before enrollment), hematological disorders and known malignancy were excluded from the study.
Coronary angiography and collateral vessel development
The extent and the severity of the coronary lesions Standard selective coronary angiography with at least 4 views of the left coronary system and 2 views of the right coronary artery was performed to all patients using the Judkins technique. Gensini score which considers both the extent and the severity of the lesions at coronary angiography was calculated for each patient (11) . This scoring system grades the stenosis in the epicardial coronary arteries (1 for 1-25% stenosis, 2 for 26-50% stenosis, 4 for 51-75% stenosis, 8 for 76-90% stenosis, 16 for 91-99% stenosis, and 32 for total occlusion) and multiplies this number by a constant number determined according to the anatomical position of the lesion.
Determination of coronary collateral development
We investigated the relation of circulating inflammatory cell and EPC with collateral vessel growth in the patients who had ≥ 90% stenosis in at least one major coronary artery. These patient's coronary angiograms were reevaluated for collateral development by two experienced interventional cardiologists who were totally blind to the study. Collateral grading was performed to the vessel with coronary artery stenosis of ≥90% and if the patient had more than one vessel with high-grade stenosis and collateral development; collateral grading had been defined according to vessel that had better collateral. In patients with previous coroner artery bypass grafting (CABG) operation history, if CABG grafts were diseased, it was considered as a lesion in related native vessel.
The grade of coronary collateral development was determined according to the Cohen-Rentrop (12) method: grade 0, no filling of any collateral vessels; grade 1, filling of side branches of the artery to be perfused by collateral vessels without visualization of epicardial segment; grade 2, partial filling of the epicardial artery by collateral vessels; and grade 3, as complete filling of epicardial artery by collateral vessel. Patients with grade 0-1 collateral development were regarded as poor collateral group and patients with grade 2-3 collateral development were regarded as good collateral group.
Identification and quantification of circulating EPC by flow cytometry Blood samples were drawn by venipuncture before coronary angiography. Fasting venous blood was collected in tubes with EDTA and processed within 2 hours of collection. Phycoerythrin (PE)-labeled anti-CD34 was obtained from Antibodies Direct (AbD) Serotec (Immunoglobulin G1 [IgG1]-PE) (AbD Serotec, Kidlington, UK), allophycocyanin (APC)-labelled anti-kinase domain receptor (KDR) from R&D systems (IgG1-APC) (R&D Systems Europe, Abingdon, UK) and incubation was performed following the manufacturer's instructions. All samples were pretreated with Fc receptor blocking reagent (Sigma, Saint Louis, MO, USA) for 15 minutes at room temperature to prevent non-specific binding of antibodies. For the analysis of the samples, 100 μl of whole blood was incubated with anti-KDR-APC (10μl) and anti-CD34-PE (10μl) for 30 minutes at room temperature. Incubation was followed by erythrocyte lysis (BD FACS Lysing Solution, BD Biosciences, San Jose, CA, USA) and washing in phosphate buffered saline (PBS). Flow cytometry measurement was performed using appropriate fluorescence compensation and setting for lysed whole blood excluding debris and platelets and the number of CD34 + and CD34 + /KDR + cells were analyzed in the lymphocyte and monocyte gates (mononuclear cells). At least 10.000 events were measured within the myelomonocytic gate. Respective PE-or APC-conjugated isotype control antibodies from the same manufacturers served as controls. Cells were measured using appropriate fluorescence compensation and light scatter gating in a FACSCalibur flow cytometry (Becton Dickinson, USA). Analysis was done using fluorescence-1/fluorescence-2 dot plot quadrant statistics and manual gating (Cell Quest Pro software, Becton Dickinson, BD Biosciences, San Diego, CA, USA) by a blinded approach about patient characteristics. The percentage of positive cells was converted into absolute numbers of cells/mm -3 using the white blood cell (WBC) count and the percentages of lymphocytes and monocytes obtained from an automated cell counter (Coulter Gen-S, COULTER Corp, Miami, USA). (Formula 1: Absolute cell count=EPC %totalxWBC/100, Formula 2: Absolute cell count=EPC %gatedx%GatexWBC/10.000).
Routine laboratory measurements
Blood samples were drawn by venipuncture to perform routine blood chemistry after fasting for at least 8 hours before coronary angiography. Fasting blood glucose, serum creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels were recorded. Glucose, creatinine, and lipid profile were determined by standard methods. The Friedewald's formula was used for LDL cholesterol measurement (13) . When triglyceride level exceeded 400mg/dl, the direct measurement technique was used for LDL measurement.
Statistical analysis
The SPSS statistical software (SPSS 15.0 for Windows, Inc., Chicago, IL, USA) was used for all statistical calculations. Continuous variables are given as mean±standard deviation; categorical variables ware defined as percentages. Continuous variables were compared by Mann-Whitney U test and the Chisquare test was used for comparison of categorical variables between two groups. Logistic regression analysis was used to determine independent predictors of coronary artery disease and collateral flow.
Age, hypertension, fasting blood glucose, leukocytes and subtypes and EPC were included as independent variables in the logistic regression model to predict the CAD (dependent variable). Patients with good collateral development were excluded from this analysis because of it was an uncorrectable confounding factor for this analysis.
Age, EPC and total coronary occlusion were included as independent variables in the logistic regression model to predict good coronary flow (dependent variable).
All tests of significance were two-tailed. Statistical significance was defined as p<0.05.
Results
Endothelial progenitor cells, inflammatory cells and coronary artery disease The mean age of the patients was 59±9 years. Thirty of 112 consecutive patients had normal coronary artery (NCA, 27%) and 82 had CAD (73%). Among the patients with CAD, the percent degree of luminal stenosis was <50% in 12 patients; 50-90% in 35 patients; and ≥90% in the other 35 patients. Table 1 (Table 4) .
Endothelial progenitor cells, monocytes and collateral development
We also found that patients with good collateral growth had significantly higher EPC (cell percent, p=0.009; cell count, p=0.003) ( (Fig. 2) and a CD34 -KDR -cell subpopulation within monocyte gate (514±173 mm -3 ) reached to highest counts in good collateral group in our study (Fig. 3) .
In logistic regression analysis among all independent variables like age, EPC and total coronary occlusion, only EPC was an independent predictor for good collateral growth (OR=1.295, 95%CI 1.039-1.615, p=0.02) ( Table 5 ).
Discussion
In this study, we aimed to evaluate the effects of progenitor and inflammatory cells on CAD and coronary collateral growth simultaneously. Our findings suggested that EPC is an independent predictor for coronary collateral formation despite of extensive atherosclerosis and cardiovascular risk factors. In additionally, a specific subpopulation of monocytes, which were not included the progenitors was related to good collaterals. On the other hand, EPCs reduced risk for CAD while inflammatory cells, especially neutrophils had incremental effect on CAD.
During the last half century, great advances in the treatment of acute and chronic forms of atherosclerosis have been achieved. These advances were provided by controlling of the offended risk factors for atherosclerosis and, by using evidence based drugs and devices for its clinical manifestations. Together with these advances, today additional improvement cannot be provided on reached event reduction rates for treatment of stable CAD. This treatment resistance can be broken by discovery of new cells, cytokines, receptors and regulators in vascular system.
The role of endothelium is beyond to be only a cell monolayer inside vessels. It has been understood with recognition of the novel parameters that represent endothelium health status and independently predict the all-vascular events. However, like many mature cell lines, endothelial cells have limited reparative ability, especially in pathological microenvironments produced by vascular risk factors.
Recently, it was proved that endothelium is not alone in compensation for the damaging effect of cardiac risk factors in vasculature. In this reparative process, a more important role belongs to EPC in circulation. After first time defined by Asaraha et al. (14), we have more knowledge about their source, roles, levels and functionality. Today, the treatment potential of these cells for atherosclerosis is an important research area. Different cell types and application routes are under active search for cardiac regeneration (15) .
Coronary angiogenesis and collateral growth are chronic adaptations to myocardial ischemia to restore coronary blood flow and salvage myocardium in the ischemic region. Several contributing factors have been reported in relation to collateral development. The severity of coronary artery stenosis and the duration of myocardial ischemic symptoms have been found in association with good collateral formation (16, 17) . Patients with diabetes, hypercholesterolemia, and hypertension have less ability to create collateral vessels (18) (19) (20) . Myocardial infarction and revascularization procedures may cause to decrease visible collaterals.
In a recent study related to collateral development, various cytokines were studied but insufficient results were obtained (21) . Significant relationship has been found only between monocyte functions and monocyte transcription profiling with good collateral development (22, 23) . Heterogeneity in collateral formation despite similar degrees of coronary obstruction may be related to several factors such as different effects of inflammatory cells, the capability of cell homing factors in the ischemic tissue and levels of both cytokines and chemokines related with ischemic tissue. The quantity and quality of functional cells may be critical in the development of collaterals. Besides, these stages may be operative by undefined mechanisms such as other cells, cytokines and receptors that contribute to inflammation process.
Previous experimental animal studies also demonstrated that monocytes could be important elements for development of collateral vessels (24) (25) (26) . In 1976, Schaper et al. (25) demonstrated the histological evidence for monocyte adhesion and migration to the endothelium of newly developing collateral arteries in dog hearts. More recently, in functional studies, which were done in animals, arteriogenesis has been shown to correlate directly with the concentration of circulating monocytes and the amount of accumulating monocytes/macrophages in the perivascular tissue (26 Data are presented as mean±standard deviation, median (min-max) and percentages *Mann-Whitney U and Chi-square tests **The relation of circulating inflammatory cell and EPC with collateral vessel growth was searched in the patients who had ≥ 90% stenosis in at least one major coronary artery ACEI-angiotensin converting enzyme inhibitor, ARB-angiotensin II receptor blocker, ASA-acetyl salicylic acid, BP-blood pressure, CABG-coronary bypass surgery, CAD-coronary artery disease, CD34-cluster domain 34, EF-ejection fraction, FACS-fluorescence-activated cell sorting, HDL-high-density lipoprotein, KDR-kinase insert domain receptor, LDL-low-density lipoprotein, MImyocardial infarction, NCA-normal coronary artery Table 2 . Baseline demographic, biochemichal and hematological parameters in collateral growth Rentrop groups In previous studies, we showed a positive significant correlation between the monocyte count and collateral development in diabetic (643±184 vs 479±143 mm -3 , p<0.001) and non-diabetics (671±218 vs 522±195 mm -3 , p<0.001) (27, 28) . These findings have suggested that the monocytes may have a key role in the integrity of arteriogenesis even in the clinical setting as well as in experimental studies. If monocytes have reparative functions in atherosclerosis, at least a subpopulation, the insufficiency of monocyte quality and quantity in patients with CAD may be important in all vascular reparative mechanisms.
Endothelial progenitor cell is the new aspect of collateral growth. These mononuclear cells derived from bone marrow, have been implicated in the production of new blood vessel development (9, 10) . The cells have reparative features in vasculature. Cardiovascular risk factors both attenuate the function and the amount of these cells (29) . Vascular progenitor cells are presumably counted within the monocyte population detected by Coulter analysis, and they may contribute to collateral vessel development. Therefore in the current study, we excluded all CD34 + and KDR + cell types from monocyte gate, and then when we looked redundant cells, which represented the isolated Table 5 . Logistic regression analysis of predictors for good coronary collateral development CD34 -KDR -monocytes, we found that patients with good collateral had still highest monocyte count (before exclusion, 664±219 vs 548±159 mm -3 ; after exclusion of CD34 cells, 628±210 vs 537±183 mm -3 ; after exclusion of both CD34 and KDR cells, 514±173 vs 469±162 mm -3 ). This findings support that there is a specific monocyte subpopulation other than progenitors, which has an independent function in collateral growth. Monocytes and EPCs may have common and/or different roles in the integrity of arteriogenesis.
In our study, we selected patients who underwent angiography consequently and in that way produced a spectrum for CAD. This study design provided opportunity to investigate and to compare the development of CAD and collateral growth at same population. EPC has also been evaluated together with inflammatory cells. While inflammatory cells increase with presence, severity and extent of CAD, progenitor cells decreased. Lowest value of EPC was found in poor collateral subgroup. This finding is of interest because poor and good collateral growth groups had similar atherosclerotic coronary burden determined by Gensini score and in multivariate analyses, EPC was related with good collaterals independent of chronic total coronary occlusion. Another important finding was that good collateral group has reached similar to the NCA group EPC count (21±15 vs 18±15 mm -3 , p=NS). In atherosclerotic process, EPC count and function were found to depress with vascular risk factors, but in current study population, progenitor cells again increased to nearly normal levels in good collateral group by severe coronary ischemia, despite of the severe coronary atherosclerotic burden. This increase in progenitors did not include only EPC, but also other CD34 progenitor and KDR cells too. Moreover, a sum of CD34 + KDR -, CD34 + KDR + and CD34 -KDR + cells (192±98mm -3 ) in good collateral group has reached to higher counts than the counts in NCA group (Fig. 2) . This finding shows that the response mechanisms to ischemia related with progenitors was still intact in patients with good collateral. Our findings suggest that the peripheral effect of cardiovascular risk factor on progenitors is not entirely valid for bone marrow, because if this were the case, the decreased progenitor cells would not be able reach to normal levels in good collateral group within patient spectrum of CAD.
Patients with poor collateral had lowest EPC count despite of the presence of significant ischemia. The possible causes of this insufficiency in the response must be explained. In a previous study, we found that collateral growth had inverse relation with asymmetric dimethylarginine (ADMA), which is a biological synthesis blocker of nitric oxide (NO) (30) . While this association suggests a critical role for NO on collateral development, it also supports the integral regulator function of endothelium in this process. In our opinion, there is probably a defect in ischemiainduced cytokine generation of endothelium, which affects specifically the bone marrow to mobilize progenitors.
Study limitations
Our study had some limitations. First of all, study population was relatively small. Larger study population would provide higher statistical power. The other one, in vitro cell functions, the cytokines, which are functional for collateral growth in physiologic circumstances, were not studied in this study. This kind of analysis would probably provide additional information on collateral growth and atherosclerosis. Lastly, in our study, control group included the patients who are not completely normal, because although they have angiographically normal coronary arteries they still have cardiac risk factors or may have cardiac syndrome-X. Therefore, the statistical differences would be difficult to determine between normal and pathologic group. Otherwise, our study population proved many significant relations among study groups.
It is known that collateral growth and CAD are long-lasting process and disease. Therefore, it may be thought that one-time measurement cannot represent all courses. Especially this may be true for collateral growth because of it is responsive to coronary ischemia. However, good collateral growth may not totally relieve the coronary ischemia and secondly some patients may individually have higher basal values for progenitor cells which can determine tendency for the atherosclerosis and capability for collateral development. 
Conclusion
The stimulation of collateral growth in a safe manner would have an important role in patients with no treatment option. Endothelial progenitor cells can be mobilized from bone marrow to induce the coronary collateral growth in case of myocardial ischemia even in presence of the vascular risk factors and extensive atherosclerosis. This finding may be supportive to investigate the molecules, which can specifically mobilize EPC without inflammatory cells and would be the drug of chose for regenerative medicine in vascular system.
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